Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9889144 | SUN PHARM | Abiraterone acetate formulation and methods of use |
Mar, 2034
(9 years from now) | |
US10292990 | SUN PHARM | Abiraterone steroid formulation |
May, 2034
(10 years from now) |
Market Authorisation Date: 22 May, 2018
Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer
Dosage: TABLET;ORAL